Literature DB >> 12368911

CTLA-4-Ig regulates tryptophan catabolism in vivo.

Ursula Grohmann1, Ciriana Orabona, Francesca Fallarino, Carmine Vacca, Filippo Calcinaro, Alberto Falorni, Paola Candeloro, Maria L Belladonna, Roberta Bianchi, Maria C Fioretti, Paolo Puccetti.   

Abstract

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) plays a critical role in peripheral tolerance. However, regulatory pathways initiated by the interactions of CTLA-4 with B7 counterligands expressed on antigen-presenting cells are not completely understood. We show here that long-term survival of pancreatic islet allografts induced by the soluble fusion protein CTLA-4-immunoglobulin (CTLA-4-Ig) is contingent upon effective tryptophan catabolism in the host. In vitro, we show that CTLA-4-Ig regulates cytokine-dependent tryptophan catabolism in B7-expressing dendritic cells. These data suggest that modulation of tryptophan catabolism is a means by which CTLA-4 functions in vivo and that CTLA-4 acts as a ligand for B7 receptor molecules that transduce intracellular signals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12368911     DOI: 10.1038/ni846

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  358 in total

1.  Expression of Stat3 and indoleamine 2, 3-dioxygenase in cornea keratocytes as factor of ocular immune privilege.

Authors:  Jae Wook Yang; Dong Sik Ham; Hyun Woong Kim; Sul Gee Lee; Sae Kwang Park; Su Kil Seo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-11-10       Impact factor: 3.117

Review 2.  Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Authors:  Xiang-Yang Wang; Daming Zuo; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Pharmacother       Date:  2011-12       Impact factor: 3.889

Review 3.  Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases.

Authors:  G C Prendergast; M Y Chang; L Mandik-Nayak; R Metz; A J Muller
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

4.  Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.

Authors:  Matteo Vergati; Vittore Cereda; Ravi A Madan; James L Gulley; Ngar-Yee Huen; Connie J Rogers; Kenneth W Hance; Philip M Arlen; Jeffrey Schlom; Kwong Y Tsang
Journal:  Cancer Immunol Immunother       Date:  2010-10-26       Impact factor: 6.968

Review 5.  Dendritic cells, T cell tolerance and therapy of adverse immune reactions.

Authors:  P A Morel; M Feili-Hariri; P T Coates; A W Thomson
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

6.  PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells.

Authors:  P'ng Loke; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-15       Impact factor: 11.205

7.  Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.

Authors:  Madhav D Sharma; Babak Baban; Phillip Chandler; De-Yan Hou; Nagendra Singh; Hideo Yagita; Miyuki Azuma; Bruce R Blazar; Andrew L Mellor; David H Munn
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

8.  Regulatory T-cell markers, indoleamine 2,3-dioxygenase, and virus levels in spleen and gut during progressive simian immunodeficiency virus infection.

Authors:  Adriano Boasso; Monica Vaccari; Anna Hryniewicz; Dietmar Fuchs; Janos Nacsa; Valentina Cecchinato; Jan Andersson; Genoveffa Franchini; Gene M Shearer; Claire Chougnet
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

9.  Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents.

Authors:  A Picchianti Diamanti; M M Rosado; M Scarsella; V Germano; E Giorda; S Cascioli; B Laganà; R D'Amelio; R Carsetti
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

Review 10.  Targeting Type 1 Diabetes: Selective Approaches for New Therapies.

Authors:  Daniel F Sheehy; Sean P Quinnell; Arturo J Vegas
Journal:  Biochemistry       Date:  2019-01-17       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.